Companies › PharmaEssentia
1 active drug program in 10 registered trials: 4 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ropeginterferon Alfa-2B (P1101) Interferon alpha/beta receptor positive modulator | IFNAR1, IFNAR2 | Phase 3 | Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) … | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06770842 | Ropeginterferon Alfa-2B (P1101) | Phase 2 | Primary Myelofibrosis (PMF) | Oncology | Dec 2026 |
| NCT05482971 | Ropeginterferon Alfa-2B (P1101) | Phase 2 | Essential Thrombocythemia | Oncology | Mar 2027 |
| NCT05485948 | Ropeginterferon Alfa-2B (P1101) | Phase 2 | Polycythemia Vera | Oncology | Jul 2027 |
| NCT05481151 | Ropeginterferon Alfa-2B (P1101) | Phase 3 | Polycythemia Vera | Oncology | Jul 2027 |
| NCT06468033 | Ropeginterferon Alfa-2B (P1101) | Phase 3 | Primary Myelofibrosis | Oncology | Nov 2027 |
| NCT07047885 | Ropeginterferon Alfa-2B (P1101) | Phase 1 | Cutaneous T Cell Lymphoma | Oncology | Jun 2028 |
| NCT07646821 | Ropeginterferon Alfa-2B (P1101) | Phase 1 | Ropeginterferon | Oncology | Dec 2028 |
| NCT07521046 | Ropeginterferon Alfa-2B (P1101) | Phase 1 | Myelofibrosis | Oncology | Aug 2029 |
| NCT04285086 | Ropeginterferon Alfa-2B (P1101) | Phase 3 | Essential Thrombocythemia | Oncology | Aug 2029 |
| NCT07269470 | Ropeginterferon Alfa-2B (P1101) | Phase 2 | Chronic Myeloid Leukemia | Oncology | Nov 2029 |
Diakonos Oncology BriaCell Therapeutics Brii Biosciences Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical
3D Medicines (Sichuan) Protagonist Therapeutics Greenwich LifeSciences Diakonos Oncology Jiangsu Healthy Life Innovation Medical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.